Yoshiko Hirano1, Hirokazu Oguni2, Mutuko Shiota1, Aiko Nishikawa1, Makiko Osawa1. 1. Department of Pediatrics, Tokyo Women's Medical University, Tokyo 162, Japan. 2. Department of Pediatrics, Tokyo Women's Medical University, Tokyo 162, Japan. Electronic address: hoguni@ped.twmu.ac.jp.
Abstract
PURPOSE: Ketogenic diet therapy (KD) has been used to treat children with refractory generalized epilepsy. We herein reported the efficacy of KD for West syndrome (WS) resistant to ACTH therapy. SUBJECTS: SUBJECTS, consisting of 6 patients (3 boys, 3 girls) with WS who continued to have epileptic spasms (ES) and hypsarrhythmia, received KD because other treatments including ACTH therapy failed to control WS. METHODS: We retrospectively studied the clinical details of these patients and the efficacy of KD. RESULTS: The mean age at the onset of epilepsy was 4 months (0-15 months). The underlying etiology consisted of lissencephaly, Down's syndrome, and focal cortical dysplasia. Hypsarrhythmia disappeared 1 month after the introduction of KD in 5 patients. The disappearance of ES was achieved in 2 patients, the frequency of ES episodes was 80% less in 3, and no change was observed in 1. Psychomotor development was promoted in 5 patients, along with improvements in ES and EEG. Gastrointestinal complications and lethargy, presumably caused by rapid ketosis, were reported as side effects in 3 patients during the first week of KD. Side effects including lethargy, anorexia, and unfavorable weight gain continued thereafter in these patients in spite of tolerance to KD. CONCLUSION: KD was effective for WS resistant to ACTH therapy, although gastrointestinal side effects should be considered when introducing KD to milk-fed infants.
PURPOSE: Ketogenic diet therapy (KD) has been used to treat children with refractory generalized epilepsy. We herein reported the efficacy of KD for West syndrome (WS) resistant to ACTH therapy. SUBJECTS: SUBJECTS, consisting of 6 patients (3 boys, 3 girls) with WS who continued to have epilepticspasms (ES) and hypsarrhythmia, received KD because other treatments including ACTH therapy failed to control WS. METHODS: We retrospectively studied the clinical details of these patients and the efficacy of KD. RESULTS: The mean age at the onset of epilepsy was 4 months (0-15 months). The underlying etiology consisted of lissencephaly, Down's syndrome, and focal cortical dysplasia. Hypsarrhythmia disappeared 1 month after the introduction of KD in 5 patients. The disappearance of ES was achieved in 2 patients, the frequency of ES episodes was 80% less in 3, and no change was observed in 1. Psychomotor development was promoted in 5 patients, along with improvements in ES and EEG. Gastrointestinal complications and lethargy, presumably caused by rapid ketosis, were reported as side effects in 3 patients during the first week of KD. Side effects including lethargy, anorexia, and unfavorable weight gain continued thereafter in these patients in spite of tolerance to KD. CONCLUSION: KD was effective for WS resistant to ACTH therapy, although gastrointestinal side effects should be considered when introducing KD to milk-fed infants.
Authors: Susan Harvey; Nicholas M Allen; Mary D King; Bryan Lynch; Sally A Lynch; Mary O'Regan; Declan O'Rourke; Amre Shahwan; David Webb; Kathleen M Gorman Journal: Dev Med Child Neurol Date: 2022-01-29 Impact factor: 4.864